Bookmaker pleads guilty to improper conduct at Paddington Heath
A betting company which won the lottery at Paddington Heath has been sentenced to six months in prison after pleading guilty to a series of charges.
Matthew Pugh, 32, admitted nine charges - three of indecent assault, three of making indecent images of children, two of sending obscene messages and three of possessing an obscene photograph.
He pleaded guilty at Glasgow Sheriff Court.
Pugh, from St Andrews, was due to be sentenced in October. He was given suspended jail terms.
Judge Alan Clarke said the offences of the most serious offence involving indecent assault involved a seven year old girl, and another was an indecently assaulting a child.
'The victim had been sexually abused by the defendant when he was the owner of the sports betting business at Paddington Heath,' Clarke said.
'The offence of making indecent photographs of children was particularly serious. A child victim was sexually abused by the defendant.
'There are other serious offences involving indecent photographs of children which are in progress.
'In these offences one of the victims was an adult and the other was an adolescent.'
A Crown Office spokesman said: 'We are aware of the sentencing decision of Matthew Pugh, the defendant responsible for a series of offences involving child sexual exploitation and we are consulting with the Crown Prosecution Service in preparing our responses to the Court of Appeal.
'We will work to the fullest extent to respond to the appeal.'
An inquiry was launched in the wake of the Paddington Heath scandal and a full investigation is under way following its conclusion.
The Crown Office are investigating the investigation and are also assisting police with their inquiries.
For more information visit www.gov.uk/gov-uk-paddington-heath
A spokesperson said: 'We are aware of the outcome of the court proceedings involving Matthew Pugh of The Paddington Group.
'A joint investigation is ongoing and we are providing our ongoing support.
'The case has been referred to the Public Prosecution Service to ensure that the relevant law is carried out.
'We understand from the legal guidance produced by the prosecution that Mr Pugh could not be convicted for the offences against the child he had abused.
'The Public Prosecution Service will continue to review the case carefully to address the important matters of protection for victims of sexual abuse and we would ask people to remain calm in the face of the complex nature of these matters and their impact. 바카라사이트 바카라
Sars vaccine could be ready within three years, after an estimated $50 million cost overruns, experts say. (AP Photo/Tass)
BEST VALUES, but not quite: Despite the price tag, there are some important considerations that will be important for everyone involved. The most important thing is quality control. Sars vaccine could be ready within three years, after an estimated $50 million cost overruns, experts say.
The cost overruns have been widely blamed on Sars, and some vaccine industry figures say that even if it were true, it is unlikely.
As in any company's acquisition process, there was an early and significant delay in testing, so the results are now more reliable than before. The results for the vaccine, which is made by Sanofi Pasteur, the company that manufactured Sars, "could be delivered within weeks," Michael Smith, executive vice president of vaccine portfolio management at the FDA.
But even more important, the vaccine doesn't have yet to go to market in the United States.
"We can't have these uncertainties and risk," says Stephen Ralston, director of the infectious diseases program at the Johns Hopkins Bloomberg School of Public Health. "We also have to take care of our own, and that requires being responsible about costs, not giving all the details to a competitor. So for us to have confidence, it means that there are important risks."
There are two kinds of information that might affect the costs associated with Sars vaccines:
One, because of how well or badly Sars has affected those who had it in the first few weeks, researchers know more now about how the vaccine might work. So they are prepared to estimate the costs in a year or two and to add to that the anticipated costs of the treatment afterward, which researchers say would add more to the total. And that means that their cost estimates become more precise, the risk less. The second is because of what is known about how the virus is spread, such as how it comes into people's bodies and if they catch it.
That is a big risk, because all vaccines have risks, and some also have benefits.
BEST VALUES, but not quite: Even if these two types of information become more accurate, the total cost is likely to be much larger and some vaccines could be ready much sooner.
That's because scientists are working to make sure that when they make their Sars vaccine they do not make it in the wrong form. They are working on how to minimize the risk of false positives, so that it makes sense if patients get the correct version and do not catch Sars.
Even if Sars vaccine was in form that it's difficult to make, it's possible to minimize th